A dual vaccine candidate against norovirus and hepatitis E virus

Vaccine

Volumn 32, Issue 4, 2014, Pages 445-452

  Wang, Leyi ^a,d   Cao, Dianjun ^c   Wei, Chao ^a   Meng, Xiang Jin ^c   Jiang, Xi ^a,b   Tan, Ming ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^d Animal Disease Diagnostic Laboratory   (United States)

Author keywords

Bivalent vaccine; Hepatitis E virus (HEV); Immune response; Norovirus; Polyvalent complex; Vaccine development; Vaccine platform

Indexed keywords

GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE NOROVIRUS P DOMAIN HEPATITIS E VIRUS P DOMAIN FUSION PROTEIN; HEPATITIS E VACCINE; HYBRID PROTEIN; NOROVIRUS P DOMAIN HEPATITIS E VIRUS P DOMAIN FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HEPATITIS E; IMMUNOGENICITY; LIGAND BINDING; MOUSE; NONHUMAN; NOROVIRUS INFECTION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; TREATMENT RESPONSE; VIRUS NEUTRALIZATION;

BIVALENT VACCINE; HEPATITIS E VIRUS (HEV); IMMUNE RESPONSE; NOROVIRUS; POLYVALENT COMPLEX; VACCINE DEVELOPMENT; VACCINE PLATFORM;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; FEMALE; HEP G2 CELLS; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; NOROVIRUS; RECOMBINANT FUSION PROTEINS; VIRAL VACCINES;

EID: 84891629059     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.064     Document Type: Article

References (47)

1. Patel M.M., Widdowson M.A., Glass R.I., Akazawa K., Vinje J., Parashar U.D. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008, 14:1224-1231.
2. Panda S.K., Thakral D., Rehman S., Hepatitis E virus. Rev Med Virol 2007, 17:151-180.
3. Kumar S., Subhadra S., Singh B., Panda B.K., Hepatitis E virus: the current scenario. Int J Infect Dis 2013, 17:e228-e233. IJID: official publication of the International Society for Infectious Diseases.
4. Kamar N., Selves J., Mansuy J.M., Ouezzani L., Peron J.M., Guitard J., et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008, 358:811-817.
5. Meng X.J. Recent advances in hepatitis E virus. J Viral Hepat 2010, 17:153-161.
6. Khuroo M.S., Teli M.R., Skidmore S., Sofi M.A., Khuroo M.I. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981, 70:252-255.
7. Jaiswal S.P., Jain A.K., Naik G., Soni N., Chitnis D.S. Viral hepatitis during pregnancy. Int J Gynaecol Obstet 2001, 72:103-108. The official organ of the International Federation of Gynaecology and Obstetrics.
8. M X.J., Anderson D.A., Arankalle V.A., Emerson S.U., Harrison T.J., Jameel S. Hepeviridae. Virus Taxonomy, 9th Report of the ICTV London 2012, 1021-1028. Elsevier Academic Press, London. A.M.Q. K, M.J. Adams, E.B. Carstens, E.J. Lefkowitz (Eds.).
9. Prasad B.V., Hardy M.E., Dokland T., Bella J., Rossmann M.G., Estes M.K. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999, 286:287-290.
10. Xing L., Li T.C., Mayazaki N., Simon M.N., Wall J.S., Moore M., et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem 2010, 285:33175-33183.
11. Li S., Tang X., Seetharaman J., Yang C., Gu Y., Zhang J., et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 2009, 5. e1000537.
12. Bu W., Mamedova A., Tan M., Xia M., Jiang X., Hegde R.S. Structural basis for the receptor binding specificity of Norwalk virus. J Virol 2008, 82:5340-5347.
13. Cao S., Lou Z., Tan M., Chen Y., Liu Y., Zhang Z., et al. Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol 2007, 81:5949-5957.
14. Chen Y., Tan M., Xia M., Hao N., Zhang X.C., Huang P., et al. Crystallography of a lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog 2011, 7. e1002152.
15. Choi J.M., Hutson A.M., Estes M.K., Prasad B.V. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci USA 2008, 105:9175-9180.
16. Tan M., Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol 2005, 13:285-293.
17. Tan M., Jiang X. Norovirus-host interaction: implications for disease control and prevention. Expert Rev Mol Med 2007, 9:1-22.
18. Tan M., Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog 2010, 6. e1000983.
19. Tan M., Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol 2011, 19:382-388.
20. He S., Miao J., Zheng Z., Wu T., Xie M., Tang M., et al. Putative receptor-binding sites of hepatitis E virus. J Gen Virol 2008, 89:245-249.
21. Fang H., Tan M., Xia M., Wang L., Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One 2013, 8(4):e63269. in press.
22. Li S.W., Zhang J., Li Y.M., Ou S.H., Huang G.Y., He Z.Q., et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005, 23:2893-2901.
23. Zhang J., Gu Y., Ge S.X., Li S.W., He Z.Q., Huang G.Y., et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005, 23:2881-2892.
24. Tan M., Jiang X., Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) 2012, 7:889-897.
25. Proffitt A. First HEV vaccine approved. Nat Biotechnol 2012, 30:300.
26. Richardson C., Bargatze R.F., Goodwin R., Mendelman P.M. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013, 12:155-167.
27. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011, 365:2178-2187.
28. Wang L., Huang P., Fang H., Xia M., Zhong W., McNeal M.M., et al. Polyvalent complexes for vaccine development. Biomaterials 2013, 34:4480-4492.
29. Tan M., Meller J., Jiang X. C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein. J Virol 2006, 80:7322-7331.
30. Mori Y., Matsuura Y. Structure of hepatitis E viral particle. Virus Res 2011, 161:59-64.
31. Ahmad I., Holla R.P., Jameel S. Molecular virology of hepatitis E virus. Virus Res 2013, 161:47-58.
32. Tan M., Hegde R.S., Jiang X., The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J Virol 2004, 78:6233-6242.
33. Tan M., Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005, 79:14017-14030.
34. Tan M., Zhong W., Song D., Thornton S., Jiang X. E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability. J Med Virol 2004, 74:641-649.
35. Tan M., Huang P., Xia M., Fang P.A., Zhong W., McNeal M., et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011, 85:753-764.
36. Tan M., Fang P.A., Xia M., Chachiyo T., Jiang W., Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology 2011, 410:345-352.
37. Huang P., Farkas T., Marionneau S., Zhong W., Ruvoen-Clouet N., Morrow A.L., et al. Noroviruses bind to human ABO Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003, 188:19-31.
38. Huang P., Farkas T., Zhong W., Tan M., Thornton S., Morrow A.L., et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005, 79:6714-6722.
39. Sanford B.J., Emerson S.U., Purcell R.H., Engle R.E., Dryman B.A., Cecere T.E., et al. Serological evidence for a hepatitis E virus-related agent in goats in the United States. Transbound Emerg Dis 2012.
40. Emerson S.U., Clemente-Casares P., Moiduddin N., Arankalle V.A., Torian U., Purcell R.H. Putative neutralization epitopes and broad cross-genotype neutralization of hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol 2006, 87:697-704.
41. Fritz-Wolf K., Becker A., Rahlfs P., Harwaldt K., Schirmer R.H., Kabsch W., et al. X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci USA 2003, 100:13821-13826.
42. Frenck R., Bernstein D.I., Xia M., Huang P., Zhong W., Parker S., et al. Predicting susceptibility to norovirus GII. 4 by use of a challenge model involving humans. J Infect Dis 2012, 206:1386-1393.
43. Han L., Kitov P.I., Kitova E.N., Tan M., Wang L., Xia M., et al. Affinities of recombinant norovirus P dimers for human blood group antigens. Glycobiology 2013, 23:276-285.
44. Fiege B., Rademacher C., Cartmell J., Kitov P.I., Parra F., Peters T. Molecular details of the recognition of blood group antigens by a human norovirus as determined by STD NMR spectroscopy. Angew Chem 2012, 51:928-932.
45. Han L., Kitova E., Tan M., Jiang X., Klassen J. Identification of carbohydrate ligands of a norovirus P particle using a catch and release electrospray ionization mass spectrometry assay. J Am Soc Mass Spectrom 2013, in press.
46. Xia M., Tan M., Wei C., Zhong W., Wang L., McNeal M., et al. A candidate dual vaccine against influenza and noroviruses. Vaccine 2011, 29:7670-7677.
47. Yang Y., Xia M., Tan M., Huang P., Zhong W., Pang X., et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol 2010, 84:9595-9607.